- Home
- AB vs GPCR Comparison
AB vs GPCR Comparison
Compare AB & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AB | GPCR |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AB | GPCR |
|---|---|---|
| Price | $35.08 | $27.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $39.57 | ★ $105.78 |
| AVG Volume (30 Days) | 309.3K | ★ 1.2M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.58 | $25.59 |
| 52 Week High | $44.11 | $94.90 |
Technical Indicators
Market Signals| Indicator | AB | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.75 | 19.59 |
| Support Level | N/A | N/A |
| Resistance Level | $37.70 | $56.63 |
| Average True Range (ATR) | 0.56 | 1.89 |
| MACD | -0.08 | -0.60 |
| Stochastic Oscillator | 22.71 | 8.88 |
Price Performance
Historical ComparisonAbout AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (40%), and private (18%) clients through products that include mutual funds, hedge funds, and separately managed accounts. At the end of July 2026, the company had $909.0 billion in managed assets, composed primarily of fixed-income (35% of AUM) and equity (40%) strategies, with other investments (including asset allocation services and certain other alternative investments) accounting for the remainder.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.